RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.
17 Dec, 2021 | 09:50h | UTCInvited commentary: Anticoagulation in COVID-19 – The Lancet
Commentary on Twitter
NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE trial https://t.co/OWcmjCLBTw pic.twitter.com/3Bl4lV16Va
— The Lancet (@TheLancet) December 16, 2021